Theriva Biologics Inc - TOVX Accounting Value per Share

Official company branding of Theriva Biologics (TOVX)

The development of VCN-01 oncolytic adenoviruses for pancreatic therapy by Theriva Biologics, Inc. (TOVX) is currently in the active monitoring stage. A team of virologists and oncologists is focused on protecting the gut microbiome. Management is ensuring the transparency of European tests, although capitalization remains dependent on equity offerings. The book value per share reflects asset dynamics, where 0.27 determines the current status of the parameter.

TOVX Synthetic Biologics Net Asset Value per Share (04/28/2023 - 10/30/2026)

TOVX (therivabio.com): analytical breakdowns and indicator data

- share price and expert price forecast:
Stock Quotes Synthetic Biologics|TOVX - Price Target Chart
- issuer market value details:
Market Valuation Theriva Biologics, Inc.|TOVX - Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share Theriva Biologics|TOVX - Total Stockholders' Equity|Market Value to Book Value Ratio therivabio.com|TOVX - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Capital Theriva Biologics, Inc.|TOVX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Theriva Biologics|TOVX - Company Cumulative Debt|Debt to Book Capitalization Ratio Theriva Biologics, Inc.|TOVX - Company Long-Term Debt|Company Short-Term Debt Theriva Biologics|Quick Ratio therivabio.com
- earnings and multiples data:
TOVX - Annual Net Income
Basic company analysis:TOVX - Synthetic Biologics
Manufactured products of Theriva Biologics

Assessing the reliability of equity assets begins with an analysis of net assets, where the calculated value per share is determined as the difference between all company assets and liabilities, divided by the number of shares. For Theriva Biologics, Inc. (TOVX), which depends on oncology R&D results, the current book value per share reflects the actual capital cushion and the efficiency of utilizing grants to cover operating expenses.

Competitor analysis for Theriva Biologics, Inc.

IBRX: Accounting Value per Share|IMCR: Net Assets per Single Share|JANX (Janux Therapeutics) - Accounting Value per Share|Equity per Share RCUS|Net Assets per Single Share Zymeworks|Net Asset Value per Share Tango Therapeutics Inc TNGX|Net Assets per Single Share Iovance (IOVA)|Immatics Biotechnologies - Equity per Share|Book Value per Share XNCR (Xencor, Inc.)|CMPX - Accounting Value per Share|REPL - Net Assets per Single Share|Net Asset Value per Share Lyell|Innate Pharma, S.A. (IPHA) - Net Assets per Single Share|PYXS (Pyxis Oncology) - Net Assets per Single Share|Net Assets per Single Share Compugen Ltd|Net Asset Value per Share iobiotech.com IOBT|Book Value per Share STRO|MiNK Therapeutics Inc. (INKT) - Book Value of One Share|Werewolf Therapeutics, Inc. - Accounting Value per Share|Immix Biopharma Inc. (IMMX) - Net Asset Value per Share|ALXO: Accounting Value per Share|Accounting Value of a Share CUE (cuebiopharma.com)|PDSB: Book Value per Share|SONN - Net Assets per Share|Net Assets per Single Share MAIA Biotechnology Inc|Accounting Value per Share Liminatus (LIMN)|Net Assets per Single Share LAVA Therapeutics N.V. (LVTX)|Accounting Value per Share nextcure.com NXTC|Leap Therapeutics - Accounting Value per Share|Book Value per Share Intensity Therapeutics Inc INTS|SNSE - Net Assets per Single Share|GRTS (Gritstone bio, Inc.) - Equity per Share|Kineta, Inc. (KA) - Net Assets per Single Share|Net Asset Value per Share neximmune.com (NEXI)|Accounting Value per Share TSBX|VCNX - Book Value of One Share|Accounting Value per Share HARP (Harpoon Tx)